Filing Details
- Accession Number:
- 0000899243-20-007820
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-03-10 21:14:39
- Reporting Period:
- 2020-03-02
- Accepted Time:
- 2020-03-10 21:14:39
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1723128 | Amneal Pharmaceuticals Inc. | AMRX | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1738054 | Gautam Patel | C/O Cepheid Capital, Llc 277 W. 4Th Street, Unit 2 New York NY 10014 | Yes | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Class A Common Stock | Acquisiton | 2020-03-02 | 32,111 | $3.88 | 38,218 | No | 4 | P | Direct | |
Class A Common Stock | Acquisiton | 2020-03-03 | 117,889 | $3.94 | 156,107 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Direct | |
No | 4 | P | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Class A Common Stock | 12,887,433 | Indirect | See Footnote |
Footnotes
- The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.84 to $3.90, inclusive.
- The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.86 to $4.00, inclusive.
- By trusts which the reporting person may be deemed to control. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.